Testing a new antibody therapy for treatment-resistant blood cancer

Plain-English translation of NCT04643002 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a medication called , which is an antibody designed to fight multiple myeloma — a blood cancer that has become resistant to previous treatments. Researchers are studying how well this medication works when combined with different partner drugs and doses. The goal is to find the best combination to help patients whose myeloma has come back or stopped responding to earlier therapies.

Multiple myeloma often comes back or becomes resistant to standard treatments, leaving patients with limited options. This trial exists to find new combinations of medications that might work better for people in this difficult situation, potentially offering hope when other treatments have stopped working.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with relapsed or refractory multiple myeloma and have already received at least two previous treatment regimens
your myeloma can be measured by blood or urine tests, or by free light chain blood tests
you have an Eastern Cooperative Oncology Group performance status of 0 or 1, meaning you are well enough to carry out most normal activities
you are willing to use contraception if you are a man or woman of childbearing potential

You likely don't qualify if…

you have primary systemic amyloidosis, plasma cell leukemia, or smoldering myeloma
you have an active or uncontrolled infection in the past 14 days
you have had significant heart or vascular disease in the past 3 months, such as a heart attack, stroke, or severe heart failure
you have untreated or active hepatitis B or C, or HIV disease requiring treatment
you have had recent severe allergic reactions or significant safety concerns with anti-CD38 therapy (depending on which substudy you might join)

What participation looks like

If you join this trial, you will receive intravenous infusions of the study medication on a regular schedule — some weekly and some every two weeks — combined with oral pills taken by mouth. You will continue treatment for up to about 28 months unless your disease gets worse, you experience unacceptable side effects, or you and your doctor decide to stop. You will have regular visits to monitor how well the treatment is working and to check for any side effects.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(26 sites)

United States

Winship Cancer Institute of Emory University- Site Number : 8400010, Atlanta, Georgia

University of Illinois-Chicago - College of Medicine- Site Number : 8400007, Chicago, Illinois

University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan

Roswell Park Cancer Institute- Site Number : 8400008, Buffalo, New York

The Ohio State University- Site Number : 8400012, Columbus, Ohio